Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 12/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL882971 | 0.85 | MTNR1A (0.47) | KMOTDP1POLBMTNR1AMTNR1B | |
| SCHEMBL31403767 | 0.85 | MTNR1A (0.47) | KMOTDP1POLBMTNR1AMTNR1B | |
| SCHEMBL28051846 | 0.83 | NNMT (0.50) | TDP1POLBMTNR1AMTNR1BKDM4E | |
| SCHEMBL31344571 | 0.83 | ALDH1A1 (0.47) | TDP1POLBMTNR1AMTNR1BKDM4E | |
| SCHEMBL6635914 | 0.80 | KDR (0.44) | TDP1POLBMTNR1AMTNR1BKDM4E | |
| SCHEMBL27884234 | 0.80 | MTNR1A (0.43) | KMOTDP1POLBMTNR1AMTNR1B | |
| SCHEMBL20931377 | 0.79 | P2RX7 (0.52) | POLBMTNR1AMTNR1BLMNAKDM4E | |
| SCHEMBL3406277 | 0.78 | MTNR1A (0.45) | TDP1POLBMTNR1AMTNR1BFFAR1 | |
| SCHEMBL1324299 | 0.78 | CYP1A2 (0.45) | POLBMTNR1AMTNR1BLMNAKDM4E | |
| SCHEMBL30711661 | 0.78 | ATR (0.39) | KMOTDP1POLBMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326754-A1 | DNA-PK Inhibitor Compounds and Uses Thereof | ADMARE THERAPEUTICS SOC (CA) | 2025-10-23 | — | — | US | disclosed |
| CN-119350323-B | N-sulfonyl amide nitrogen-containing fused heterocycle compounds targeting p53 mutation and application thereof | 上海宇道生物技术有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4522620-A1 | DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF | Admare Therapeutics Society (CA) | 2025-03-19 | — | — | EP | disclosed |
| CN-119350323-A | N-sulfonyl amide nitrogen-containing fused heterocycle compounds targeting p53 mutation and application thereof | 上海宇道生物技术有限公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-07-25 | — | — | US | disclosed |
| EP-4305031-A1 | 7-MORPHOLINO-L,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | Admare Therapeutics Society (CA) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023215991-A1 | DNA-PK INHIBITOR COMPOUNDS AND USES THEREOF | adMare Therapeutics Society (CA) | 2023-11-16 | — | — | WO | disclosed |
| EP-3600312-B1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-17 | — | — | EP | disclosed |
| CN-110520127-B | Piperidinyl-substituted and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | 武田药品工业株式会社 | 2023-05-16 | — | — | CN | disclosed |
| WO-2022187964-A1 | 7-MORPHOLINO-L,6-NAPHTHYRIDIN-5-YL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF USEFUL AS DNA-PK INHIBITOR | adMare Therapeutics Society (CA) | 2022-09-15 | — | — | WO | disclosed |
| CN-110520127-A | Piperidinyl-substituted and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | TAKEDA PHARMACEUTICALS CO | 2019-11-29 | — | — | CN | disclosed |
| WO-2019002571-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2019-01-03 | — | — | WO | disclosed |
| WO-2018183145-A1 | PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | WO | disclosed |
| CN-101880280-B | Bicyclic pyrimidinones and uses thereof | SHANGHAI INST ORGANIC CHEM | 2014-07-16 | — | — | CN | disclosed |
| EP-2635279-A2 | CHEMICAL COMPOUNDS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-11 | — | — | EP | disclosed |
| US-20130225524-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| CN-101627019-B | Bicyclic pyrimidinones and uses thereof | AVEXA LTD | 2013-07-10 | — | — | CN | disclosed |
| WO-2012061557-A2 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-05-10 | — | — | WO | disclosed |
| CN-101880280-A | Bicyclic pyrimidinones and uses thereof | SHANGHAI INST ORGANIC CHEM | 2010-11-10 | — | — | CN | disclosed |
| CN-101627019-A | Bicyclic pyrimidinones and uses thereof | AVEXA LTD | 2010-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246960-A1 | 7-Morpholino-L,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | KMO 1857/4885TDP1 32/4885POLB 42/4885 |
| US-20130225524-A1 | Chemical Compounds | LDHA, NQO2, LDHB | KMO 400/4885TDP1 1504/4885POLB 1119/4885 |
| US-20250326754-A1 | DNA-PK Inhibitor Compounds and Uses Thereof | DCK, CHEK1, CHEK2 | KMO 1967/4885TDP1 28/4885POLB 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.